16 March 2021

Dr. Vladimir Cmiljanovic: “RocketVax SARS-CoV-2 vaccine should be effective regardless of the mutation occurring on the spike protein”

CEO of RocketVax, Dr. Vladimir Cmiljanovic, gave an interview about the development of the second-generation SARS-CoV-2 vaccine for RTS (Serbian Broadcasting Corporation).

“The first-generation vaccines are focused on one of the virus’s proteins – the so-called spike protein. They train our immune system by exposing the coronavirus spike protein to our immune cells. The so produced spike protein antibodies can then recognize the spike protein of the wild-type virus when the real virus infection occurs, and this is how our immune system is trained by that first generation of vaccines.

We take another approach, which is to train our – human – immune system against all possible coronavirus proteins. This means that our vaccine should be effective regardless of the mutation occurring on the spike protein.”

Follow our LinkedIn, Instagram, and Facebook page to keep up with our progress.

PREVIOUS NEWS NEXT NEWS